CDC20抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: SKOV3 and Hela cell lysates, Primary antibody: P07177(CDC20 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P07177(CDC20 Antibody) at dilution 1/200. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07177(CDC20 Antibody) at dilution 1/200. (Original magnification: ×200)    

  
  

CDC20 (Cell Division Cycle 20) is a critical regulatory protein involved in cell cycle progression, specifically during the transition from metaphase to anaphase in mitosis. As a key coactivator of the Anaphase-Promoting Complex/Cyclosome (APC/C), CDC20 facilitates the ubiquitination and subsequent degradation of mitotic regulators like securin and cyclin B, ensuring proper chromosome segregation and mitotic exit. Dysregulation of CDC20 is closely associated with genomic instability, aberrant cell proliferation, and tumorigenesis, making it a biomarker of interest in cancer research.

CDC20 antibodies are essential tools for studying its expression, localization, and functional interactions in cell cycle control. They are widely used in techniques such as Western blotting, immunofluorescence, immunohistochemistry (IHC), and flow cytometry to quantify CDC20 levels in normal versus pathological tissues. Overexpression of CDC20 has been reported in various cancers, including breast, colorectal, and hepatocellular carcinomas, correlating with poor prognosis and therapeutic resistance. Researchers also employ these antibodies to investigate CDC20's role in checkpoint mechanisms, drug responses, and its potential as a therapeutic target.

Recent studies explore CDC20 inhibitors to disrupt cancer cell proliferation, highlighting its translational relevance. Commercial CDC20 antibodies are typically raised against specific epitopes (human or murine) and validated for species reactivity and application compatibility.